Covid19NCT04374513
Community Pharmacists Behaviour During Covid-19
An observational study of Covid19, run by Damanhour University at 2 sites in Egypt.
Trial summary
During the COVID-19 pandemic, governments issued movement restrictions and placed areas into quarantine to reduce the spread of the disease.Community pharmacists and their teams are a vital healthcare provider during the outbreak; they remain on the frontline of public health by serving as direct points of access for… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Covid19
- How many people
- 318 participants
- Where
- 2 sitesEgypt
- Study dates
- 2 Apr 2020to 1 Jul 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: community pharmacists
Who may be able to join
- Post graduated pharmacist. Community pharmacists.
Who cannot join
- under graduated students. not pharmacist.
Trial locations and contacts
2 sites in 1 country.
Egypt2 sites
Damanhour universty
Alexandria, 11865
Damanhour university
Beheira, Damanhour, 22511
About this study
Official title: SURVEY of RETAIL PHARMACISTS KNOWLEDGE, ROLE & BEHAVIOR DURING COVID-19 VIRUS OUTBREAK
During the COVID-19 pandemic, governments issued movement restrictions and placed areas into quarantine to reduce the spread of the disease.Community pharmacists and their teams are a vital healthcare provider during the outbreak; they remain on the frontline of public health by serving as direct points of access for their patients. The retail pharmacists should provide public community, costumers and patients with right and trusted information about covid-19. They also should have role in awareness spreading regarding personnel safety and hygiene
Read the detailed description
The survey will enroll as many community pharmacists as possible in the survey portion of the study - The number of participates have no limitations, at least 50 participants.
The survey will be enrolled in online google form, face to face interview \& semi-structured telephone interviews if possible.
The research procedures:
- An online survey link will include questions regarding the impact of role and behavior of retail pharmacists during covid-19 outbreak.
- Face to face and semi-structured interviews if possible: For those pharmacists who state that they would like to participate in an interview, a random sample will be contacted.
Inclusion Criteria:
- Post graduated pharmacist.
- Community pharmacists.
Exclusion Criteria:
- under graduated students.
- not pharmacist.
- Conditions
- Covid19
- Keywords
- Pharmacists/ covid-19
- Medical subject headings
- COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
community pharmacists facing covid-19
Evaluate the knowledge, role \& behavior of retail pharmacists in facing covid-19 virus through the survey
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2020
- Study start2 Apr 2020
- Primary completion1 Jun 2020
- Study completion1 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 318 participants (actual)
Sponsor and investigators
- Lead sponsor
- Damanhour University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Asser Ghoneim, phD, Principal investigator, Professor in Pharmacology, Faculty of pharmacy, Damanhour University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04374513
- Sponsor's protocol ID
- Pharmacists and covid-19
- Status last verified
- Apr 2020
- First submitted
- 2 May 2020
- Last updated
- 3 Feb 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Farooq A, Laato S, Islam AKMN. Impact of Online Information on Self-Isolation Intention During the COVID-19 Pandemic: Cross-Sectional Study. J Med Internet Res. 2020 May 6;22(5):e19128. doi: 10.2196/19128.
PubMed 32330115Bukhari N, Rasheed H, Nayyer B, Babar ZU. Pharmacists at the frontline beating the COVID-19 pandemic. J Pharm Policy Pract. 2020 Apr 20;13:8. doi: 10.1186/s40545-020-00210-w. eCollection 2020.
PubMed 32328285Rutter V, Chan AHY, Tuck C, Bader L, Babar ZU, Bates I. Weaving the health and pharmaceutical care agenda through the themes of the commonwealth heads of government meeting (CHOGM), London 2018. J Pharm Policy Pract. 2018 Apr 11;11:10. doi: 10.1186/s40545-018-0140-3. eCollection 2018.
PubMed 29651337
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SURVEY of RETAIL PHARMACISTS KNOWLEDGE, ROLE & BEHAVIOR DURING COVID-19 VIRUS OUTBREAK
- ClinicalTrials.gov ID
- NCT04374513
- Acronym / sponsor ID
- Pharmacists and covid-19
- Conditions
- Covid19
- Keywords
- Pharmacists/ covid-19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 318 participants (actual)
- Lead sponsor
- Damanhour UniversityUniversity, hospital or other
- Study start
- 2 Apr 2020 (actual)
- Primary completion
- 1 Jun 2020 (actual)
- Study completion
- 1 Jul 2020 (actual)
- First posted
- 5 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
During the COVID-19 pandemic, governments issued movement restrictions and placed areas into quarantine to reduce the spread of the disease.Community pharmacists and their teams are a vital healthcare provider during the outbreak; they remain on the frontline of public health by serving as direct points of access for their patients. The retail pharmacists should provide public community, costumers and patients with right and trusted information about covid-19. They also should have role in awareness spreading regarding personnel safety and hygiene
Detailed description
The survey will enroll as many community pharmacists as possible in the survey portion of the study - The number of participates have no limitations, at least 50 participants.
The survey will be enrolled in online google form, face to face interview \& semi-structured telephone interviews if possible.
The research procedures:
- An online survey link will include questions regarding the impact of role and behavior of retail pharmacists during covid-19 outbreak.
- Face to face and semi-structured interviews if possible: For those pharmacists who state that they would like to participate in an interview, a random sample will be contacted.
Inclusion Criteria:
- Post graduated pharmacist.
- Community pharmacists.
Exclusion Criteria:
- under graduated students.
- not pharmacist.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- community pharmacists
Key inclusion criteria (1 listed)
- Post graduated pharmacist. Community pharmacists.
Key exclusion criteria (1 listed)
- under graduated students. not pharmacist.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
community pharmacists facing covid-19
Time frame: 6 months
Evaluate the knowledge, role \& behavior of retail pharmacists in facing covid-19 virus through the survey
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2021.
- Background: PubMed 32330115Farooq A, Laato S, Islam AKMN. Impact of Online Information on Self-Isolation Intention During the COVID-19 Pandemic: Cross-Sectional Study. J Med Internet Res. 2020 May 6;22(5):e19128. doi: 10.2196/19128.
- Background: PubMed 32328285Bukhari N, Rasheed H, Nayyer B, Babar ZU. Pharmacists at the frontline beating the COVID-19 pandemic. J Pharm Policy Pract. 2020 Apr 20;13:8. doi: 10.1186/s40545-020-00210-w. eCollection 2020.
- Background: PubMed 29651337Rutter V, Chan AHY, Tuck C, Bader L, Babar ZU, Bates I. Weaving the health and pharmaceutical care agenda through the themes of the commonwealth heads of government meeting (CHOGM), London 2018. J Pharm Policy Pract. 2018 Apr 11;11:10. doi: 10.1186/s40545-018-0140-3. eCollection 2018.
Related trials for Covid19
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruitingObservational study
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Asser Ghoneim, phD principal investigator
Professor in Pharmacology, Faculty of pharmacy, Damanhour University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19, run by Damanhour University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
community pharmacists facing covid-19 (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04374513, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2021.